One product done straight versus many products done broadly: brand access with insurance navigation, against a menu of formats and tiers.
The two models
Ro plays the insurance-navigation game better than most of the category: coverage checks, prior-authorization support, and — since its 2025 arrangement to dispense Lilly’s Zepbound vials — a direct lane to brand product at manufacturer self-pay prices. Its own fees, effective monthly totals, and compounded posture remain in our verification queue, so no Ro figure appears here yet.
Orderly Meds competes on format breadth — injectables plus oral formats across multiple dose tiers — which makes it a natural comparison shop but also multiplies the price-table complexity where teaser structures hide. Its dose-tier pricing is queued for verification; oral-format claims inherit our standing evidence caveats.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Depth versus breadth
Ro concentrates its value where product is scarce and paperwork is hard; Orderly spreads across injectables and orals where format evidence varies wildly. Menu breadth shops well and prices opaquely — more tiers, more cells, more places entry rates diverge from maintenance truth — which is exactly what verification exists to flatten. Until both rows fill in the ledger, structure is the honest comparison.
Go deeper
Full files: Ro · Orderly Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.